Immutep (ASX:IMM) has announced positive results from a Phase 2b trial of its eftilagimod alfa in combination with MSD's KEYTRUDA (pembrolizumab) for head and neck cancer. …
Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 4 September
September 4, 2026 - - Podcast -
A three-pronged expansion of Commonwealth reach in therapeutic-goods regulation
September 4, 2026 - - Latest News -
If the government gives itself more power, don't be surprised when they use it
September 4, 2026 - - Latest News -
Medicines Australia calls for doubling of PBS medicines investment
September 4, 2026 - - Latest News -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - - Latest News -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - - Latest News